Key Technologies
LCT’s lead product DiabeCell® in Phase I/IIa Clinical Trials for Type 1 Diabetes
- Insulin-producing porcine islet cells within micro-capsules injected into abdomen using a laparoscopic procedure
- Targeted to patients with poor control of blood glucose
- Proprietary micro-encapsulation technology
- No immunosuppressive drugs required or used
- Lead product: DiabeCell® in Phase I/IIa clinical trials
- Patients in clinical trials during 2007 to 2008
- Preliminary data shows significant reduction in daily insulin requirements
LCT’s DiabeCell® Advantages
- No immunosuppressive drugs are used or needed
- Laparoscopic surgery can be performed by general surgeon; expensive transplant team and center not needed
- Neonatal porcine islet cells - supply is potentially unlimited
- Pigs are relatively easy to breed
- Porcine insulin and human insulin differ by only one amino acid and have nearly identical binding properties and activity
- Porcine insulin has been used therapeutically for 80 years to treat Type 1 Diabetes
- Islet cells of uniform quality and free of infectious agents
- Significantly less expensive than human islet transplant
Competitive Advantages of Company
- Unique and exclusive biocertified pig herd
- cGMP cell manufacturing facilities for clinical trials
- Accredited diagnostic laboratory, accepted in 45 countries
- Broad issued patent portfolio
- Published long-term data on lead product
